Inotek Pharmaceuticals To Expand Phase 2 Clinical Trial In Glaucoma Based On Promising Preliminary Results

Inotek Pharmaceuticals Corp., a leader in the development of innovative medicines to address significant diseases of the eye, today announced that the Company has successfully completed the first two of three stages of a multiple-dose Phase 2b clinical trial of its novel eye-drop candidate, INO-8875, in patients with glaucoma or ocular hypertension...

Full Story →